' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

ARDELT MAXIMILIAN ALEXANDER
Universitätsinstitut für Pharmazie

Publikationen

9 Publikationen

2019

Beiträge in Fachzeitschriften

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Ardelt, MA; Fröhlich, T; Martini, E; Müller, M; Kanitz, V; Atzberger, C; Cantonati, P; Meßner, M; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Hepatology. 2019; 69(1):376-393
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Cdk5 Inhibition - The Key to Enhancing the Standard of Care in Hepatocellular Carcinoma Treatment.
Ardelt, MA; Fröhlich, T; Martini, E; Müller, M; Kanitz, V; Atzberger, C; Cantonati, P; Meßner, M; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society ; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)
Potential to improve the therapeutic situation of HCC patients - The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC.
Ardelt, MA; Huber-Cantonati, P; Pachmayr, J;
10. Paracelsus Science Get Together Abstractband 2019. 2019; -10. Paracelsus Science Get Together ; 28.06.2019; Nürnberg.
Abstracts (Zeitschrift)
Potential to improve the therapeutic situation of HCC patients - The influence of Regorafenib and Lenvatinib treatment in combination with Cdk5 inhibition in HCC.
Ardelt, MA; Huber-Cantonati, P; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)
Diamonds in the rough - With low application Antibiotics against Tumor Relapse of sorafenib-resistant Hepatocellular Carcinoma.
Meßner, M; Zischka, H; Schmitt, S; Ardelt, MA; Huber-Cantonati, P; Fröhlich, T; Arnold, GJ; Atzberger, C; Müller, M; Pein, H; Koeberle, A; Zobel, LM; Koenig, L; Vollmair, AM; Pachmayr, J;
Final Programme & Book of Abstracts.. 2019; -26th Scientific Congress of the Austrian Pharmaceutical Society ; 25.-27.04.2019; Graz.
Abstracts (Zeitschrift)

2018

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Inhibition of Cdk5 - Introducing New Strategies to Prevent Sorafenib Treatment Escape in HCC Cells.
Ardelt, MA; Fröhlich, T, Martini, E; Müller, M; Kanitz, V; Atzberger, C; Posselt, L; Lehr, T; Wojtyniak, JG; Ulrich, M; Arnold, GJ; König, L; Parazzoli, D; Zahler, S; Rothenfußer, S; Mayr, D; Gerbes, A; Scita, G; Vollmar, AM; Pachmayr, J;
Paracelsus Science Get Together Abstractband 2018.. 2018; 98-98.-Paracelsus Science Get Together 2018; 29.6.2018; Paracelsus Medizinische Privatuniversität Salzburg. (ISBN: 978-3-200-05737-1 )
Abstracts (Zeitschrift)
Epithelial-to-mesenchymal transition and evasive PI3K/Akt pathway activation contribute to Sorafenib-resistance of Hepatocellular Carcinoma.
Meßner, M; Ardelt, MA; Fröhlich, T; Arnold, GJ; Vollmar, AM; Pachmayr, J;
Paracelsus Science Get Together Abstractband 2018.. 2018; 175-175.-Paracelsus Science Get Together 2018; 29.6.2018; Paracelsus Medizinische Privatuniversität Salzburg. (ISBN: 978-3-200-05737-1 )
Abstracts (Zeitschrift)

2017

Beiträge in Fachzeitschriften

Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT
Merk, H; Messer, P; Ardelt, MA; Lamb, DC; Zahler, S; Muller, R; Vollmar, AM; Pachmayr, J
MOL CANCER THER. 2017; 16(11): 2329-2339.
Originalarbeiten (Zeitschrift)

2015

Beiträge in Fachzeitschriften

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.
Ehrlich, SM; Liebl, J; Ardelt, MA; Lehr, T; De Toni, EN; Mayr, D; Brandl, L; Kirchner, T; Zahler, S; Gerbes, AL; Vollmar, AM;
J Hepatol. 2015; 63(1):102-113
Originalarbeiten (Zeitschrift)